Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
08 févr. 2021 09h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
06 janv. 2021 17h29 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
22 déc. 2020 18h07 HE
|
Supernus Pharmaceuticals, Inc.
Met primary endpoint with robust statistical significanceShowed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significanceShowed statistically significant onset...
Supernus to Participate in Annual Piper Sandler Healthcare Conference
18 nov. 2020 22h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at Two November Investor Conferences
11 nov. 2020 23h14 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
09 nov. 2020 18h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Third Quarter 2020 Financial Results
03 nov. 2020 16h30 HE
|
Supernus Pharmaceuticals, Inc.
Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020 operating earnings of $56.1 millionOn track to initiate commercial...
Supernus to Host Third Quarter 2020 Financial Results Conference Call
27 oct. 2020 17h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
05 oct. 2020 16h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments
14 sept. 2020 08h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...